Skip to content
Menu

Barclays Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $50

Benzinga Newsdesk 16 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $53 to $50.

Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $53 to $50.

Read at benzinga.com

← All stock news